Roivant Sciences Reports Positive Phase 2 Results for Lung Disease Treatment

Roivant Sciences announced positive Phase 2 clinical trial results for a lung disease drug, which was originally acquired from Bayer. These findings indicate potential progress in developing new treatments for respiratory conditions, offering hope for patients and further advancing the drug's development pathway.